To provide accessible and innovative genetic technologies, products and services for all.
Sansure Biotech Inc. is an in vitro diagnostic solution provider integrating diagnostic reagents, instruments and independent clinic laboratory services with its own innovative gene technology as its core. The company is committed to becoming a genetic technology provider, and is a National Demonstration Centre for the Application of Genetic Testing Technology and a National Joint Local Engineering Research Center for Genetic Diagnosis of Infection Diseases and Tumours.
Headquartered in Changsha, the company has built the new Industrial Park in Shanghai to create a production base for precise and intelligent molecular diagnostic systems and an important international hub, and set up branches or affiliates in nearly 20 cities, including Beijing, Guangzhou, Chongqing and Xi'an.
The company has developed a series of internationally leading core technologies and more than 400 products with performance exceeding the advanced level at home and abroad. All of the new technologies and products have lead the domestic industry to catch up with the international advanced level, and is now breaking the monopoly of imports and promoting the application of gene technology from individual departments to multiple departments in medical institutions, from high-end laboratories in large hospitals to all levels of hospitals including primary medical institutions, and from a few fields to all scenarios.
At the earliest phase of COVID pandemic, Sansure was among the first batch of companies to have developed a series of scientific and technological anti epidemic products such as new nucleic acid detection reagents and rapid detection instrument. At present, the SARS-Cov-2 nucleic acid detection products developed by Sansure biotech have served the first line of epidemic prevention and control in more than 160 countries and regions around the world, and have donated nearly 170 million yuan worth of anti-pandemic goods to domestic and foreign countries, helping thousands of domestic and foreign laboratories to increase their nucleic acid detection capabilities from scratch or several times to tens of times, providing the local with anti-pandemic nucleic acid detection solutions for many countries and regions around the world, the occupation ratio exceeds 80% market share in some countries, which also enables countries around the world to further understand China's anti-pandemic solutions and experiences and highlight China's strength.